Intercil® Uveal Spacer
Chart
A New Course
For patients who need more than MIGS, the path to bleb-free IOP control starts outside the angle.
The Middle Segment
When MIGS is no longer enough, what comes next?
As glaucoma progresses, finding the right surgical step for patients becomes increasingly challenging.
Some patients reach a point where MIGS may no longer provide the level of control they need, yet moving directly to a bleb-forming procedure may feel disproportionate to where they are in their treatment journey.
For these patients, the challenge is not recognising that treatment needs to escalate, but identifying a meaningful next step that can deliver the required IOP reduction while preserving future treatment flexibility.
The significant step up
Meaningful efficacy through a standalone procedure
In the single-centre, prospective, non-randomised SAFARI 3 (SuprAciliary Filtration Alone Reduces IOP) trial, INTERCIL® demonstrated significant and sustained reductions in IOP and medication burden — all in a standalone procedure, independent of cataract surgery.
39% IOP Reduction
Sustained to 24 months
83% Reduction in Medication
At 24 months
74% Medication Free
At 24 months
SAFARI-III Clinical Trial (NCT05236439); Voskanyan L, et al. Ophthalmol Ther. 2026 Aug 18. doi:10.1007/s40123-026-01469-z.
Think outside the angle
INTERCIL® takes a different route to IOP control
Many MIGS procedures focus on the drainage angle. INTERCIL® looks beyond it and to the eye’s natural uveoscleral outflow pathway.
But accessing this pathway has traditionally relied on creating a cyclodialysis cleft. INTERCIL® changes that. By creating controlled supraciliary spacing without cleft creation, it is designed to sustain uveoscleral outflow and deliver durable IOP reduction.
Implanted through a direct ab externo approach, INTERCIL® can be positioned precisely within the supraciliary space without entering the anterior chamber. The flexible nature of INTERCIL is designed to conform naturally within that space, providing a controlled and predictable foundation for outflow.
Precise device placement
Direct ab externo implantation into the supraciliary space supports precise device placement without anterior chamber entry.1
NATURAL OUTFLOW
Optimises the eye’s natural outflow mechanism without cleft creation.1
PREDICTABLE PERFORMANCE
Designed to deliver predictable performance in a traditionally unpredictable pathway.
Postoperative care, simplified
Powerful IOP control no longer has to mean creating a bleb
Bleb-forming procedures can require intensive postoperative monitoring and intervention to achieve optimal outcomes.
Because INTERCIL® does not create a subconjunctival bleb, its bleb-free approach is designed to streamline postoperative management compared with bleb-forming procedures.
INTERCIL® UVEAL SPACER
When MIGS is no longer enough, INTERCIL® enables earlier surgical escalation.
Significant and sustained reductions in IOP and medication burden — without a bleb
Controlled supraciliary spacing to sustain uveoscleral outflow — without creating a cleft
Designed to reduce postoperative burden – while preserving future treatment options
See the procedure
See the INTERCIL® Procedure
See how INTERCIL® is implanted through a direct ab externo approach, enabling precise placement within the supraciliary space without entering the anterior chamber or creating a cyclodialysis cleft. Watch the surgical animation to explore the key procedural steps and discover how controlled supraciliary spacing is created.
Continue the conversation
Discover how Intercil® could fit within your treatment pathway
Learn more about its clinical performance, procedure, and potential role for patients who need more than MIGS.
